List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9104524/publications.pdf Version: 2024-02-01



ΡΛΕΛΕΙ Ι ΕΔ3ΝΙ

#	Article	IF	CITATIONS
1	Enantioselective Synthesis and Pharmacological Evaluation of Aza-CGP37157–Lipoic Acid Hybrids for the Treatment of Alzheimer's Disease. Antioxidants, 2022, 11, 112.	5.1	1
2	Novel Series of Dual NRF2 Inducers and Selective MAO-B Inhibitors for the Treatment of Parkinson's Disease. Antioxidants, 2022, 11, 247.	5.1	4
3	Resveratrol-Based MTDLs to Stimulate Defensive and Regenerative Pathways and Block Early Events in Neurodegenerative Cascades. Journal of Medicinal Chemistry, 2022, 65, 4727-4751.	6.4	10
4	Curcumin-Piperlongumine Hybrids with a Multitarget Profile Elicit Neuroprotection in In Vitro Models of Oxidative Stress and Hyperphosphorylation. Antioxidants, 2022, 11, 28.	5.1	4
5	Bisavenathramide Analogues as Nrf2 Inductors and Neuroprotectors in In Vitro Models of Oxidative Stress and Hyperphosphorylation. Antioxidants, 2021, 10, 941.	5.1	13
6	Enhanced Stability and Bioactivity of Natural Anticancer Topoisomerase I Inhibitors through Cyclodextrin Complexation. Pharmaceutics, 2021, 13, 1609.	4.5	15
7	Aza GP37157â€lipoic hybrids designed as novel Nrf2â€inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties. Drug Development Research, 2020, 81, 283-294.	2.9	4
8	Melatonin-sulforaphane hybrid ITH12674 attenuates glial response in vivo by blocking LPS binding to MD2 and receptor oligomerization. Pharmacological Research, 2020, 152, 104597.	7.1	13
9	Antioxidant, Anti-inflammatory and Neuroprotective Profiles of Novel 1,4-Dihydropyridine Derivatives for the Treatment of Alzheimer's Disease. Antioxidants, 2020, 9, 650.	5.1	18
10	Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches. Handbook of Experimental Pharmacology, 2020, 264, 229-259.	1.8	20
11	When It Comes to an End: Oxidative Stress Crosstalk with Protein Aggregation and Neuroinflammation Induce Neurodegeneration. Antioxidants, 2020, 9, 740.	5.1	52
12	NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases. Biomolecules, 2020, 10, 904.	4.0	50
13	Tuning melatonin receptor subtype selectivity in oxadiazolone-based analogues: Discovery of QR2 ligands and NRF2 activators with neurogenic properties. European Journal of Medicinal Chemistry, 2020, 190, 112090.	5.5	15
14	Nrf2 Plays a Protective Role Against Intravascular Hemolysis-Mediated Acute Kidney Injury. Frontiers in Pharmacology, 2019, 10, 740.	3.5	36
15	Pharmacological doses of melatonin impede cognitive decline in tauâ€related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux. Journal of Pineal Research, 2019, 67, e12578.	7.4	53
16	Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach. Pharmacological Reviews, 2018, 70, 348-383.	16.0	441
17	The <scp>APP</scp> swe/ <scp>PS</scp> 1A246E mutations in an astrocytic cell line leads to increased vulnerability to oxygen and glucose deprivation, Ca ²⁺ dysregulation, and mitochondrial abnormalities. Journal of Neurochemistry, 2018, 145, 170-182.	3.9	4
18	MAFG is a potential therapeutic target to restore chemosensitivity in cisplatin-resistant cancer cells by increasing reactive oxygen species. Translational Research, 2018, 200, 1-17.	5.0	28

#	Article	IF	CITATIONS
19	Enzymatic and solid-phase synthesis of new donepezil-based L- and d-glutamic acid derivatives and their pharmacological evaluation in models related to Alzheimer's disease and cerebral ischemia. European Journal of Medicinal Chemistry, 2017, 130, 60-72.	5.5	21
20	Addition to "ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia― ACS Chemical Neuroscience, 2017, 8, 210-210.	3.5	2
21	Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease. Scientific Reports, 2017, 7, 45701.	3.3	59
22	Novel sulfoglycolipid IG20 causes neuroprotection by activating the phase II antioxidant response in rat hippocampal slices. Neuropharmacology, 2017, 116, 110-121.	4.1	1
23	Saffron (Crocus sativus) intake provides nutritional preconditioning against myocardial ischemia–reperfusion injury in Wild Type and ApoE (â'' â^') mice: Involvement of Nrf2 activation. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 919-929.	2.6	29
24	Inclusion complex of ITH12674 with 2-hydroxypropyl-Î ² -cyclodextrin: Preparation, physical characterization and pharmacological effect. Carbohydrate Polymers, 2017, 157, 94-104.	10.2	49
25	ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia. ACS Chemical Neuroscience, 2017, 8, 67-81.	3.5	20
26	Novel Multitarget Hybrid Compounds for the Treatment of Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2017, 17, 1027-1043.	2.1	18
27	The Antioxidant Additive Approach for Alzheimer's Disease Therapy: New Ferulic (Lipoic) Acid Plus Melatonin Modified Tacrines as Cholinesterases Inhibitors, Direct Antioxidants, and Nuclear Factor (Erythroid-Derived 2)-Like 2 Activators. Journal of Medicinal Chemistry, 2016, 59, 9967-9973.	6.4	83
28	Serine/threonine protein phosphatase PP2A as a relevant target of disulphide stress in acute pancreatitis. Free Radical Biology and Medicine, 2016, 96, S62-S63.	2.9	0
29	Nrf2–ARE pathway: An emerging target against oxidative stress and neuroinflammation in neurodegenerative diseases. , 2016, 157, 84-104.		463
30	Subthreshold Concentrations of Melatonin and Galantamine Improves Pathological AD-Hallmarks in Hippocampal Organotypic Cultures. Molecular Neurobiology, 2016, 53, 3338-3348.	4.0	23
31	Alpha7 nicotinic receptor activation protects against oxidative stress via heme-oxygenase I induction. Biochemical Pharmacology, 2015, 97, 473-481.	4.4	34
32	Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. Neuropharmacology, 2015, 99, 187-195.	4.1	34
33	New melatonin–cinnamate hybrids as multi-target drugs for neurodegenerative diseases: Nrf2-induction, antioxidant effect and neuroprotection. Future Medicinal Chemistry, 2015, 7, 1961-1969.	2.3	28
34	Anti-inflammatory role of microglial alpha7 nAChRs and its role in neuroprotection. Biochemical Pharmacology, 2015, 97, 463-472.	4.4	228
35	Melatonin–sulforaphane hybrid <scp>ITH</scp> 12674 induces neuroprotection in oxidative stress conditions by a â€~drug–prodrug' mechanism of action. British Journal of Pharmacology, 2015, 172, 1807-1821.	5.4	36
36	The Melatonin– <i>N</i> , <i>N</i> -Dibenzyl(<i>N</i> -methyl)amine Hybrid ITH91/IQM157 Affords Neuroprotection in an in Vitro Alzheimer's Model via Hemo-oxygenase-1 Induction. ACS Chemical Neuroscience, 2015, 6, 288-296.	3.5	27

#	Article	IF	CITATIONS
37	Neuroprotective effect of dimebon against ischemic neuronal damage. Neuroscience, 2014, 267, 11-21.	2.3	10
38	New 5-Unsubstituted Dihydropyridines with Improved Ca _V 1.3 Selectivity as Potential Neuroprotective Agents against Ischemic Injury. Journal of Medicinal Chemistry, 2014, 57, 4313-4323.	6.4	43
39	Gram‣cale Enantioselective Formal Synthesis of Morphine through an <i>ortho</i> – <i>para</i> Oxidative Phenolic Coupling Strategy. Angewandte Chemie - International Edition, 2014, 53, 13498-13501.	13.8	46
40	Neuroprotective effect of melatonin against ischemia is partially mediated by alphaâ€7 nicotinic receptor modulation and <scp>HO</scp> â€1 overexpression. Journal of Pineal Research, 2014, 56, 204-212.	7.4	93
41	Recent advances in the multitargetâ€directed ligands approach for the treatment of Alzheimer's disease. Medicinal Research Reviews, 2013, 33, 139-189.	10.5	394
42	Novel multitarget ligand ITH33/IQM9.21 provides neuroprotection in inÂvitro and inÂvivo models related to brain ischemia. Neuropharmacology, 2013, 67, 403-411.	4.1	25
43	Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents. MedChemComm, 2013, 4, 590.	3.4	22
44	Benzothiazepine CGP37157 and Its Isosteric 2′-Methyl Analogue Provide Neuroprotection and Block Cell Calcium Entry. ACS Chemical Neuroscience, 2012, 3, 519-529.	3.5	26
45	Catalytic enantioselective assembly of complex molecules containing embedded quaternary stereogenic centres from simple anisidine derivatives. Chemical Science, 2011, 2, 1487.	7.4	120
46	A Step Further Towards Multitarget Drugs for Alzheimer and Neuronal Vascular Diseases: Targeting the Cholinergic System, Amyloid-β Aggregation and Ca2++ Dyshomeostasis. Current Medicinal Chemistry, 2011, 18, 552-576.	2.4	50
47	Calcium signalling mediated through α7 and nonâ€Î±7 nAChR stimulation is differentially regulated in bovine chromaffin cells to induce catecholamine release. British Journal of Pharmacology, 2011, 162, 94-110.	5.4	27
48	Synthesis and biological assessment of diversely substituted furo[2,3-b]quinolin-4-amine and pyrrolo[2,3-b]quinolin-4-amine derivatives, as novel tacrine analogues. European Journal of Medicinal Chemistry, 2011, 46, 6119-6130.	5.5	46
49	Effects of novel tacripyrines ITH12117 and ITH12118 on rat vas deferens contractions, calcium transients and cholinesterase activity. European Journal of Pharmacology, 2011, 660, 411-419.	3.5	5
50	N-Acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer's disease. European Journal of Medicinal Chemistry, 2011, 46, 2224-2235.	5.5	46
51	Elucidating the reaction mechanism of the benzoate oxidation pathway encoded aldehyde dehydrogenase from <i>Burkholderia xenovorans</i> LB400. Protein Science, 2011, 20, 1048-1059.	7.6	3
52	Synthesis, Inhibitory Activity of Cholinesterases, and Neuroprotective Profile of Novel 1,8-Naphthyridine Derivatives. Journal of Medicinal Chemistry, 2010, 53, 5129-5143.	6.4	69
53	Structural and Biophysical Characterization of BoxC from Burkholderia xenovorans LB400. Journal of Biological Chemistry, 2009, 284, 16377-16385.	3.4	12
54	A reinvestigation of the acid-promoted heterocyclization of 2-(2-oxo-2-arylethyl)malononitriles in the presence of amines. Molecular Diversity, 2009, 13, 459-468.	3.9	6

#	Article	IF	CITATIONS
55	The Nâ€terminal tripeptide of insulinâ€like growth factorâ€l protects against βâ€amyloidâ€induced somatostatin depletion by calcium and glycogen synthase kinase 3β modulation. Journal of Neurochemistry, 2009, 109, 360-370.	3.9	33
56	Tacripyrines, the First Tacrineâ^'Dihydropyridine Hybrids, as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2009, 52, 2724-2732.	6.4	134
57	Identification and Characterization of Binding Sites on S100A7, a Participant in Cancer and Inflammation Pathways. Biochemistry, 2009, 48, 10591-10600.	2.5	20
58	Synthesis of 6-amino-1,4-dihydropyridines that prevent calcium overload and neuronal death. European Journal of Medicinal Chemistry, 2008, 43, 668-674.	5.5	33
59	New tacrine-dihydropyridine hybrids that inhibit acetylcholinesterase, calcium entry, and exhibit neuroprotection properties. Bioorganic and Medicinal Chemistry, 2008, 16, 7759-7769.	3.0	75
60	Novel Multipotent Tacrineâ``Dihydropyridine Hybrids with Improved Acetylcholinesterase Inhibitory and Neuroprotective Activities as Potential Drugs for the Treatment of Alzheimer's Disease. Journal of Medicinal Chemistry, 2006, 49, 7607-7610.	6.4	107
61	Synthesis and biological evaluation of new 4H-pyrano[2,3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause neuroprotection against calcium overload and free radicals. European Journal of Medicinal Chemistry, 2006, 41, 1464-1469.	5.5	42
62	New multipotent tetracyclic tacrines with neuroprotective activity. Bioorganic and Medicinal Chemistry, 2006, 14, 8176-8185.	3.0	40
63	Synthesis, acetylcholinesterase inhibition and neuroprotective activity of new tacrine analogues. Bioorganic and Medicinal Chemistry, 2005, 13, 1167-1175.	3.0	55
64	1,6â€Câ€H and 1,5â€Oâ€Si Insertion Reactions of Alkylidenecarbene Derivatives of Monosaccharides*. Journal of Carbohydrate Chemistry, 2005, 24, 369-377.	1.1	11
65	ITH4012 (Ethyl 5-Amino-6,7,8,9-tetrahydro-2-methyl-4-phenylbenzol[1,8]naphthyridine-3-carboxylate), a Novel Acetylcholinesterase Inhibitor with "Calcium Promotor―and Neuroprotective Properties. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 987-994.	2.5	28
66	Synthesis, electrochemical and biological studies on polyfunctionalized 4-ferrocenyl-4H-pyran and 4-ferrocenyl-1,4-dihydropyridine derivatives. Tetrahedron Letters, 2004, 45, 5203-5205.	1.4	11
67	Microwave-Enhanced Reactivity of Non-Activated Dienophiles Towards Pyrazine o-Quinodimethanes ChemInform, 2003, 34, no.	0.0	0
68	Microwave-Enhanced Reactivity of Non-Activated Dienophiles Towards Pyrazineo-Quinodimethanes. Synlett, 2002, 2002, 2037-2038.	1.8	10